<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00457652</url>
  </required_header>
  <id_info>
    <org_study_id>Rosuva01</org_study_id>
    <nct_id>NCT00457652</nct_id>
  </id_info>
  <brief_title>Does Caffeine Reduce Rosuvastatin-Induced Protection Against Ischemia-Reperfusion Injury?</brief_title>
  <official_title>Does Caffeine Reduce Rosuvastatin-Induced Protection Against Ischemia-Reperfusion Injury?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Does caffeine reduce rosuvastatin induced protection against ischemia reperfusion injury?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rosuvastatin is a proven cholesterol lowering medicine, which hereby is assumed to achieve a
      reduction in cardiovascular events. Apart from it's cholesterol lowering action, rosuvastatin
      may also increase tolerance against ischemia-reperfusion injury. In dogs rosuvastatin
      increases the endogenous concentration of adenosine, by enhancing the activity of the enzyme
      ecto-5'-nucleotidase, which converts adenosine monophosphate into adenosine. We hypothesize
      that rosuvastatin increases tolerance against ischemia-reperfusion injury by induction of
      ecto-5'-nucleotidase and thereby increasing adenosine activity. This protective effect of
      rosuvastatin can be abrogated by using the adenosine receptor antagonist caffeine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The targeting of Technetium 99 labeled Annexin A5 is recorded with a gamma camera as a endpoint measure of ischemia-reperfusion damage.</measure>
    <time_frame>60 and 240 minutes after ischemic exercise</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Workload (product of 50% of the maximum forearm force and duration of the ischemic exercise)</measure>
    <time_frame>during 10 minutes of ischemic exercise</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of one-week treatment of rosuvastatin 20mg once daily on lipid spectrum.</measure>
    <time_frame>before and after 7day treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The caffeine serum concentration after 24 hour abstinence .</measure>
    <time_frame>morning after 24 hours abstinence of caffeine</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Ischemia Reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7 day treatment rosuvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>7 day treatment placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>7 day treatment rosuvastatin 20mg</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  age between 18-50 yrs

          -  signed informed consent

        Exclusion Criteria:

          -  Cardiovascular disease

          -  Hypertension (systole &gt; 140 mmHg, diastole &gt; 90 mmHg)

          -  Hypercholesterolemia (fasting total cholesterol &gt; 6,0 mmol/l)

          -  Drug abuse

          -  Concomitant medication use

          -  Inability to perform the ischemic isometric muscle contraction

          -  Diabetes Mellitus (fasting glucose &gt; 7.0 mmol/L or random glucose &gt; 11.0 mmol/L)

          -  Alanine-Amino-Transferase (ALAT) &gt;90U/L (more than twice the upper level of the normal
             range)

          -  Creatinine Kinase (CK) &gt;340U/L (more than twice the upper level of the normal range)

          -  Participation in any trial concerning medicinal products during the last 60 days prior
             to this study.

          -  Participation in clinical trial involving
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerard Rongen, MD, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMCN st. Radboud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMCN st.Radboud</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Rongen GA, Oyen WJ, Ramakers BP, Riksen NP, Boerman OC, Steinmetz N, Smits P. Annexin A5 scintigraphy of forearm as a novel in vivo model of skeletal muscle preconditioning in humans. Circulation. 2005 Jan 18;111(2):173-8. Epub 2004 Dec 27.</citation>
    <PMID>15623546</PMID>
  </reference>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2007</study_first_submitted>
  <study_first_submitted_qc>April 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2007</study_first_posted>
  <last_update_submitted>April 14, 2008</last_update_submitted>
  <last_update_submitted_qc>April 14, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2008</last_update_posted>
  <responsible_party>
    <name_title>G Rongen</name_title>
    <organization>dept Pharmacology toxicology UMCN</organization>
  </responsible_party>
  <keyword>Rosuvastatin</keyword>
  <keyword>Caffeine</keyword>
  <keyword>Ischemia</keyword>
  <keyword>Reperfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

